June 1, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the return of the Biotherapies Pavilion at the 2024 AABB Annual Meeting, which will take place Oct. 19-22 in Houston, Texas. AABB introduced the inaugural Biotherapies Pavilion in 2023 as a specially designed networking space in the Exhibit Hall, providing biotherapies companies with new and curated opportunities to network with key audiences in the field and gain access to all that the AABB Annual Meeting has to offer including: [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products.
Company awarded commercial Drug Establishment License (DEL) for Canada following successful inspection of C3i’s contract development and manufacturing organization (CDMO) facility.
Montreal, Quebec (Canada), June. 19, 2024 — C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.
The approval follows an inspection by the cell and gene therapy experts from Health Canada. The DEL approval recognizes C3i as having industry-leading expertise, regulatory know-how, and strong quality standards. [Read more…]
StemCyte Renews Contract with the California Cord Blood Collection Program, Expands Therapeutic Programs
BALDWIN PARK, Calif., May 23, 2024 — StemCyte, a leader in cord blood-based regenerative therapeutics in Southern California, is excited to announce the renewal of its partnership with the California State Umbilical Cord Blood Collection Program (CA-UCBCP). In collaboration with UC Davis Health, the CA-UCBCP has helped StemCyte enhance cord blood collection efforts. [Read more…]
Anocca AB and Shinobi Therapeutics to Develop Allogeneic TCR Engineered iPSC-derived T-Cell Therapies (TCR-iPS-T) for Solid Tumors
SÖDERTÄLJE, Sweden and SAN FRANCISCO and KYOTO, Japan, May 30, 2024 — Anocca AB (Anocca), a leading T-cell receptor-engineered T-cell (TCR-T) therapeutics company, and Shinobi Therapeutics (Shinobi), developer of immune-evasive induced pluripotent stem cell (iPSC)-derived CD8 αβT-cell therapies (iPS-T), today announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies (TCR-iPS-T) for solid tumors. [Read more…]
Accelerated Biosciences Announces License of its Human Trophoblast Stem Cells (hTSC) to Agathos Biologics for Development of Ethically Sourced Research and Biomanufacturing Platforms
PHILADELPHIA, June 05, 2024 — Accelerated Biosciences Corp. (“Accelerated Bio”) is excited to announce a strategic partnership with Agathos Biologics aimed at developing ethically derived cell lines from Accelerated Bio’s human Trophoblast Stem Cells (“hTSC”) for manufacturing complex biologics. This collaboration marks a significant step towards replacing cell lines derived from aborted fetal tissue, including the widely used Human Embryonic Kidney cell line (HEK293), with new, ethically sourced human cell lines. [Read more…]
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 144
- Next Page »